fense model predicts that the probability of successful defense is lessened with inadequate record keeping, a patient that has metastasis and is alive, and a delay in diagnosis of 12 months or more. The overall indemnity model predicts a higher indemnity with the spread of disease at the time of evaluation, a patient who has metastasis and is alive, and a date of occurence closer to the present. Indemnity is less in patients who have had a lymph node dissection, who have died, or who are alive without metastasis. The WHP model predicts an increased overall indemnity with the spread of disease at the time of evaluation and the presence of a mass without pain. Indemnity decreases with a history of pregnancy, absence of presenting symptoms, or presentation with pain with or without a mass, and the performance of a lymph node dissection.
T he risk management of breast cancer is in many ways a reflection of the clinical approach of the medical community to the early diagnosis and treatment of breast cancer. The current U.S. health care system allows major disparities in quality. In the absence of uniform guidelines for excellence, the system often becomes a frustrating maze for the people it is intended to serve. To conduct a clinical breast examination (CBE) in one setting, a mammographic or sonographic evaluation in another, and a fine needle aspiration (FNA), core, or surgical biopsy somewhere else is not ideal (1) .
Early breast cancer is often very difficult to diagnose, and the correct diagnosis is usually the result of multiple complementary examinations. Each examination reveals Abstract: The goal of this study was to determine whether factors associated with the successful defense and cost of malpractice cases involving the failure to diagnose breast cancer could be identified in medical and legal records. Secondary goals were to develop a multidisciplinary clinical algorithm utilizing National Comprehensive Cancer Network (NCCN) practice guidelines with practitioner risk management strategies. Physician deviations from these guidelines were tracked to identify high-risk areas in the diagnosis of breast cancer. A multidisciplinary clinical algorithm was introduced and practitioner risk management issues were addressed. In this study specific medical, legal, and cost factors were retrospectively abstracted and analyzed to identify associations between medical and legal factors and medicolegal outcome. ProMutual handled 156 malpractice cases involving breast cancer between January 22, 1986 , and November 20, 1997 . Of the total, 124 cases involving 212 defendants were closed. The closed cases were analyzed, using multivariable stepwise logistic and linear regression, to identify associations between clinical factors and case outcome. Women's health practitioners (WHPs), including obstetrician-gynecologists (OB-GYNs), family medicine, and internal medicine clinicians, were the largest group of defendants (97). Others included radiologists (43), surgeons (33) , and pathologists (3). OB-GYNs accounted for 31% of these defendants, with a cost of more than $16 million. The greatest number of specialists represented in the open cases were radiologists, with 38% of the total. The de-different characteristics of breast tissue, benign or malignant. A CBE evaluates symmetry, contour, texture, nodularities, masses, tenderness, and nipple discharge. Mammographic examination provides information about variations in density. Ultrasound provides information about variations in tissue sound transmission. Cytologic evaluation reveals the microscopic appearance of the cells and other tissue components. There is no best or "most specialized" test. Each has its place and its limitations. The relative value of a test varies among patients and situations.
Early diagnosis of breast cancer is especially difficult in young patients with dense breast tissue. Dense fibroglandular tissue can obscure the diagnosis for both the evaluating clinician and the radiologist. A general policy of risk prevention should focuss on understanding which patients and physicians fall into a high-risk profile for diagnostic errors. Kern (2) identified a "triad of errors" involving young patients with self-discovered breast masses and negative mammograms, who accounted for the majority of breast cancer cases. Studies of such cases found that these patients, when diagnosed at stage II or higher, are more likely to file claims (3) (4) (5) (6) (7) .
Breast cancer studies have shown that when litigation is pursued for alleged failure to diagnose, multiple specialists are named in the suit. These specialists include, in descending order of frequency, women's health practitioners (WHPs), surgeons, radiologists, and pathologists (8) (9) (10) (11) . WHPs include obstetrician-gynecologists (OB-GYNs) and family and internal medicine clinicians. A recent trend has been an increase in the number of lawsuits against health maintenance organizations (HMOs) and insurance companies (12) . Malpractice claims against pathologists for misdiagnosis of breast cancer cases have been sharply rising, especially in the area of fine needle aspiration (FNA) with inadequate sampling (13,14). Lawsuits against radiologists nearly doubled between 1988 and 1992. This is due to the increasing frequency of interventional procedures radiologists are performing and their failure to obtain informed consent (15) (16) (17) . Misdiagnosed breast cancer is the leading malpractice claim within general surgery (2) . WHPs, especially gynecologists, are the most cited specialists in lawsuits, perhaps because patients frequently consider gynecologists to be the primary physicians for evaluating breast disorders (6, 8, 11, 18) .
According to surveys conducted by the Physician Insurers Association of America (PIAA) in 1990 and 1995, breast cancer ranks number one in claims frequency among misdiagnosed conditions (2, 8, 18) . The most common reason given by the majority of the expert reviewers for the delay in diagnosis in the PIAA study was, "Physical findings failed to impress the physician."
The purpose of ProMutual's study was to identify clinical and risk management factors that could help physicians make an earlier diagnosis of breast cancer. Medical and legal records were used to identify factors that resulted in increased malpractice risk for the defendant physicians. Review by data abstractors of specific deviations from routine National Comprehensive Cancer Network (NCCN) practice guidelines by defendants resulted in the creation of a multidisciplinary clinical algorithm among involved specialties (19). Multispecialty risk management issues are addressed.
MATERIALS AND METHODS
ProMutual provides professional liability coverage for more than 70% of all practitioners in Massachusetts. A total of 156 breast cancer cases were handled by ProMutual between January 22, 1986 , and November 20, 1997. The 124 cases that closed during this time period were the material for this study. Use of the model to predict results for years outside the range of data have two serious dangers: (a) Because the year will be far from the mean of the data, small errors in the parameter estimates produce large errors in the predicted indemnity; (b) The shape of the curve may change radically for later years and be badly represented by the model. Demographic, medical, and legal information available for each case was abstracted. This review included a detailed history, physical examination, mammography, and pathology data. Plaintiff and defense presentations were reviewed. To determine the length of the delay in diagnosis we considered both the delays documented by objective information and those speculated by the plaintiff and defense experts. Total defense costs are the total of indemnity payments plus expenses. Study variables are found in Table 1 .
Logistic regression and Fisher's exact test were used to test the independence of the successful defense of the suit from clinical and legal factors. Variables thought to have clinical or legal relevance or for which preliminary univariate analysis suggested a relationship between potential explanatory variables and the dependant variable were retained for multivariable analysis. The model of successful defense of a suit was developed by use of the LOGISTIC procedure of the SAS statistical software package (SAS Institute, Cary, NC). The response variable is log odds ϭ ln{ p /(1 -p )}, where p is the probability of success. Stepwise selection was used to choose the explanatory variables for the final model. Least-squares regression was used to identify the relationship between various clinical and legal factors and case indemnity. Variables thought to have clinical or legal relevance or for which preliminary univariate analysis suggested a relationship between potential explanatory variables and the dependant variable were retained for multivariable analysis. Models for continuous response variables were developed using the REG procedure of the SAS statistical software package. The case indemnity was transformed to the natural log of indemnity in order to minimize violation of the assumptions of least squares regression. The R 2 method with the C ( P ) statistics of Mallows was used to make a preliminary selection of explanatory variables (20) . Dates are defined as the number of years after January 1, 1986.
A multidisciplinary clinical algorithm was created based on ProMutual's historical breast cancer claims data in accordance with the NCCN practice guidelines. Realizing that current trends in the evaluation of breast cancer have evolved, the algorithm was then modified to reflect current paradigms. Defendants' deviations from these accepted guidelines were noted and compared to case closure with and without indemnity.
RESULTS
The 156 malpractice cases alleging negligence in the diagnosis and/or treatment of breast cancer included 124 closed cases with 212 defendants and 32 open cases with 65 defendants. Many cases involved more than one defendant from multiple medical specialties and corpo- Table 2 .
Of the 124 closed cases, 86 (69%) resulted in an indemnity payment. A total of 82 cases were settled out of court, with a mean indemnity of $422,644 and a mean expense of $46,890. The highest mean indemnity ($783,450) and expense ($99,126) resulted from four jury verdicts for the plaintiff (Table 3) . Twelve of the 124 (10%) cases were pregnancy related and 9 of these resulted in the payment of indemnity. The mean indemnity payment in pregnancy-related cases was $725,030 versus $406,045 for non-pregnancy-related cases ( Table 4) .
The surgeons incurred the highest percentage of cases that closed with indemnity (76%), followed by pathologists (67%), WHPs (55%), and radiologists (26%). The average indemnity paid out by ProMutual was highest for the WHPs. This was followed closely by surgeons and corporations, for example, HMOs (Table 5) .
Based on these data, three models were developed to explain indemnity payment and the probability of successful defense of a case. Potential explanatory variables considered for multivariable analysis in the development of the model predicting successful defense of a case are shown in Table 6 . Settlement date, use of tamoxifen, and spread of disease were not included in the final model because they were found not to have statistical significance in multivariable analysis.
where x is the log odds of a successful defense.
The model for a successful defense demonstrates that inadequate record keeping is associated with a lower likelihood of winning the case. The lowest chance of a successful defense is with a plaintiff who is alive with metastasis ( O 2 ). A successful defense is more likely if the plaintiff has died ( O 3 ). The highest chance of winning occurs when a patient is living and without metastasis ( O 1 ).
With respect to delay in diagnosis the lowest chance of a successful defense occurs when the delay is 12 months or more ( D 2 ). A successful defense is more likely when the delay in diagnosis is 6 months or more, but less than 12 months ( D 1 ). The highest chance of winning is when the delay in diagnosis is less than 6 months ( D 0 ). Overall this demonstrates that the longer the delay the lower the probability of a successful defense.
The potential explanatory variables considered for multivariable analysis in the development of the model for overall indemnity paid by ProMutual in a lost case is shown in Table 7 . The explanatory variables were identified by least-squares regression performed on the 86 cases. The variables bone marrow transplant, smoke, node dissection is associated with lower indemnity in this model. Date of loss and date of loss squared jointly describe increasing indemnity during the study period. This reflects both general inflation and a change in legal practice (see Fig. 1 ). The combination of date of loss and date of loss squared determine the shape of this curve.
The WHP model was developed using the same method as the overall indemnity model, with restriction by defendant specialty. The potential explanatory variables considered for multivariable analysis in the development of the model for indemnity incurred by WHPs are shown in The WHP model demonstrates that indemnity is increased with the spread of disease at the time of evaluation (consistent with the overall indemnity model). Indemnity is highest in those patients who present with a mass with no pain (P 2 ). Indemnity is less for patients who present with pain with or without a mass (P 1 ). Indemnity is the least for patients who have no presenting symptoms (P 0 ). The performance of a lymph node dissection is associated with lower indemnity. Patients who are parous at the time of diagnosis have decreased indemnity.
Review of the multidisciplinary algorithm deviations per defendant as they related to frequency and indemnity in the closed cases are shown in Table 9 . Areas of deviation per specialty relative to frequency and indemnity payments are shown in Table 10 . The most prevalent area of deviation in terms of frequency and indemnity payments for WHPs is the failure to refer for surgery or ultrasound. Seventy-five percent of these cases were young women who presented with a breast abnormality, had a negative mammogram, and for whom the physician suggested no further examination. Multidisciplinary clinical algorithms are shown in Figures 2-6 . Areas of inadequate documentation included (13), recommended follow-up (12), presenting symptom (7), altered record (4), telephone calls (3), informed (3), and illegibility (2). Multispecialty risk management concerns are the greatest in terms of number of defendants and indemnity paid in the areas of follow-up, referral, and communication (Table 11) .
DISCUSSION
According to a recent PIAA study, insurers now pay more money for breast cancer cases than for any other disease or condition except those involving brain-damaged infants (2, 18 ). This PIAA study was headlined in a recent law journal: "The Worst List-Breast Cancer Now Leading Source of Medical Malpractice Claims" (21) .
The authors of the PIAA study were impressed with the young age of most of the plaintiffs and concluded that "once a patient presents with a problem, regardless of age, a physician should treat the complaint seriously and pursue all methods available in making a diagnosis." The most common reason given for delay in diagnosis was "Physical findings failed to impress the physician"; the second most common reason was "Negative mammogram report." Kern (2) proposed that a successful risk prevention strategy depended on a better understanding of which patients and physicians fall into a high-risk profile for frequent diagnostic errors. He described a "triad of errors" for delayed diagnosis of breast cancer which profiles women at highest risk to be those under age 45 years with a self-discovered breast mass and a negative mammogram. Certainly a negative mammogram report should not deter a clinician from further evaluation in the presence of a palpable mass suspicious for carcinoma.
In young patients, masses are frequently assumed to be fibrocystic change. Both mammography and CBE are less sensitive in young patients. Kern (22) recommends that immediate tissue biopsy by fine needle aspiration biopsy (FNAB) or core-cutting needle biopsy, followed by excision of solid lesions would be cost effective and prevent the majority of diagnostic delays that lead to litigation in these high-risk women. Mitnick (23) prefers the primary use of mammography and ultrasound prior to FNAB, core-cutting biopsy, or surgical biopsy. The sensitivity of FNAB is about 90%, so 10% of carcinomas go undetected with this approach (24, 25) . Adjunctive ultrasound use in young women with dense fibroglandular tissue with suggestive dominant masses would likely reduce the false-negative rate of this technique and would further characterize cancerous lesions that can be localized for core or surgical excision at little added cost. Review of the specific portion of the multidisciplinary clinical algorithm showed that clinicians were not faulted for failure to perform a mammogram, but were faulted for failure to perform an examination, ultrasound, and/or biopsy in pregnant patients.
The successful defense model shows that the least defensible cases were those in which the plaintiff was alive with metastatic disease, there had been a delay in diagnosis of 1 year or more, and the physician's record keeping was poor. Current diagnostic paradigms assert that delay between onset of symptoms and initiation of treatment for breast cancer results in presentation at a more (22, (24) (25) (26) (27) (28) . This study demonstrates that inadequate record keeping will destroy any chance of a successful defense. The overall indemnity model indicates that indemnity payments were highest in cases in which the following three conditions were met: the plaintiff was alive but with metastatic disease, metastasis was present at the time of evaluation, and the date of occurence was closer to the present (see Fig. 1 ). Cases in which the plaintiff has already succumbed to the disease are often easier to defend than those in which the patient is still alive. The defense strategy in many of these cases revolves around determining whether earlier diagnosis would have changed clinical outcome. Expert reviewers in oncology often believe the patient's cancer to be so aggressive that earlier diagnosis would not have made a difference in the ultimate clinical course. Despite that, 70% of cases closed with an indemnity payment.
The WHP model, like the overall indemnity model, demonstrates that indemnity is increased with the spread of disease at the time of evaluation. The highest indemnity was found in cases in which the patient presented with a mass without pain. Our study showed that 77% of the lesions were initially discovered by the patient on breast self-examination. It is imperative that physicians be diligent in their imaging and pathology examinations and not act quickly to dismiss an abnormality as fibrocystic breast disease.
Indemnity was less for patients who presented with pain and for those who had no presenting symptoms. Courts lower indemnity awards somewhat if an aggressive diagnostic procedure (lymph node dissection) has been performed. In our study, 80% of the patients who had metastatic disease and were alive did not have a lymph node dissection performed. Parous patients had a lower indemnity. In summary, the indemnity in breast malpractice cases increases when system failures result in advanced disease with resulting poor prognosis. Indemnity is exacerbated when the population served is young, nulliparous, or pregnant.
CONCLUSION
The failure to diagnose breast cancer is one of the most costly types of cases for malpractice insurers. The numbers of such claims are currently increasing. In order to reduce the risk of involvement in a suit alleging "failure to diagnose cancer," physicians should incorporate certain clinical guidelines and risk management strategies in their practice. Critical to appropriate quality of care rendered is a comprehensive tracking system that incorporates documented clinical data and communication of that data with health care professionals. D'Orsi and Debor (29) recently highlighted the importance of unambiguous radiological data communicated along established guidelines using standardized Breast Imaging Reporting and Data Systems (BI-RADS) terminology. Other inclusive data kept as nonidentifiable as possible consists of patient demographics and multispecialty tissue diagnosis. Biopsy and clinically relevant data must be collected and correlated with mammographic BI-RADS interpretation for quality assessment as required under the Mammographic Quality Standards Act of 1990 (30, 31) . Positive biopsy results must be entered into state cancer registries, as required by the American College of Surgery, and can be validated with such a vehicle. Appropriate patient follow-up documentation is automated to optimize accuracy and efficiency. Communication with patients can be enhanced by providers at the initial evaluation (risk assessment, CBE, and mammography). Effective communication is most crucial when results are abnormal and additional imaging is required. In these cases, the physician might consult the algorithm developed as part of this study and refer the patient for complementary ultrasound which should be performed immediately. With inconsistent diagnostic findings, an appropriate tissue diagnosis, for example, FNAB, core-cutting needle biopsy, or open biopsy for palpable lesions, and image-guided biopsies (using ultrasound, stereotactic, or wire-guided methods) may be required. Pathology results, additional tests, and follow-up should be discussed to patient satisfaction.
With a positive diagnosis, options for specialized care are best offered in the context of regionally associated multidisciplinary breast centers. The consumer of breast services, for example, a woman with a breast abnormality under clinical breast examination, expects to receive focussed attention, with all diagnostic and treatment interventions governed by a well-planned, coordinated strategy. She needs to know that her care follows a cohe- sive plan with predetermined expectations of outcome, well adapted to her personal beliefs, lifestyle, and social circumstances. She needs to be presented with choices that are available and consistent with optimal care so that she can participate in the fundamental decisions about her care.
The referring health care provider is responsible for his/her patients' routine breast care. He/she is also responsible for the follow-up, monitoring, and tracking of women whose results are abnormal, including those for whom a biopsy is recommended according to the Agency for Health Care Policy and Research (32, 33) . This responsibility is shared with the mammography facility. The facility that performed the initial mammogram is responsible for performing or arranging for future examinations or added views and/or procedures to be performed. Each facility must have a system to track positive mammographic findings and a process for correlating findings with biopsy results (32). It also has the duty to communicate urgent or significant findings to physicians and sometimes to patients directly, as determined by the courts (16, (34) (35) (36) (37) . The Practice Standards Claims Survey (38) states that 75% of all breast cancer cases in which indemnity is paid include the allegation that the patient did not receive appropriate follow-up. This article echoes this (Table 11) .
The courts have not fully defined the duty of radiologists relative to tracking of patients after percutaneous core biopsies; however, written documentation of follow-up is mandated (39, 40) . Once a patient is under a physician's care, no matter the specialty, that physician is obligated to provide appropriate evaluation, treat- ment, and follow-up. All data gathered must be subject to objective and balanced quality assurance review to ensure its accuracy and privacy. These system changes will lead to a quality of care that is already available to patients suffering from other illnesses and will likely reduce patient dissatisfaction, unanticipated poor outcomes, and resultant litigation.
Freedom from a lawsuit alleging "failure to diagnose cancer" can never be guaranteed. However, the likelihood of involvement in such a case can be minimized if the physician uses formal guidelines to direct his/her diagnostic examination of all patients, and particularly those considered at risk, that is, young nulliparous women who present with a painless mass. The chance that a suit can be successfully defended cannot be predicted from the data presented in our study. However, these data suggest that the chance for a successful defense increases with comprehensive documentation, including notation of clinical breast examination, recommended follow-up, and the patient's presenting clinical status.
History is not an absolute predictor of the future. In breast cancer cases, however, it can help guide present clinical decision making. Physicians who have failed to make timely diagnoses of breast cancer and patients who have suffered injury or death because of those errors offer lessons for those who wish to avoid similar situations in the future. Those are the lessons upon which we have built the models and developed the multidisciplinary clinical care algorithm that are presented as the core of this article. 
